Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction
Comparing the Effects of THERA°PEARL Eye Mask (Bausch & Lomb Inc., New York, USA) With the Use of Blephasteam® (Spectrum Thea Pharmaceuticals LTD, Macclesfield, UK).
An open label, randomized controlled study in a Norwegian population with meibomian gland dysfunction. Patients will be randomized to one of two groups: THERA°PEARL Eye Mask (Bausch & Lomb Inc., New York, USA) or Blephasteam® (Spectrum Thea Pharmaceuticals LTD, Macclesfield, UK). All patients will receive Hylo-comod (URSAPHARM Arzneimittel GmbH, Saarbrücken, Germany).
Steam delivery goggles, once daily
Heat delivery device, delivering heat to the eyelids, once daily
Tear substitute containing hyaluronic acid, four times daily
Inclusion Criteria: Meibomian Gland Dysfunction Eligible for heat treatment Ocular Surface Disease Index (OSDI) >12 Quality or expressibility score ≤20 years old: >1 or >20 years old: ≥1 Non-invasive tear film break-up time (NITBUT) <10 s in at least one eye Schirmer-1 test >5 mm after 5 min Exclusion Criteria: Glaucoma, Ocular allergy Autoimmune disease Contact lens-wear during study Current punctal plugging Pregnant/lactating Candidate for topical anti-inflammatory Cicatricial meibomian gland dysfunction